Equities research analysts at Jefferies Group started coverage on shares of Dyax (NASDAQ: DYAX) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $6.00 price target on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks upgraded shares of Dyax from a “neutral” rating to an “outperform” rating in a research note to investors on Monday, January 28th. They now have a $3.90 price target on the stock.
Shares of Dyax opened at 3.27 on Tuesday. Dyax has a 52 week low of $1.32 and a 52 week high of $3.74. The stock’s 50-day moving average is currently $3.20. The company’s market cap is $324.6 million.
Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.